Influence of the subtype on local recurrence risk of breast cancer with or without radiation therapy

Wickberg, Åsa; Magnuson, Anders; Holmberg, Lars; Adami, Hans‐Olov; Liljegren, Göran

doi:10.1016/j.breast.2018.08.097

Cited by 11 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As expected, the higher T and N status were associated with higher recurrence risk, consistent with other predictive models and a large number of studies [8]. We also found that the intrinsic subtype had a strong association with relapse which is also consistent with other studies [9]. The importance of pCR as a predictive and prognostic factor in LABC is well known and was also seen in our patients also.…”

Section: Discussionsupporting

confidence: 92%

A Simple Risk Scoring System for Predicting Recurrence in Women with Locally Advanced Breast Cancer (LABC) Treated with Neoadjuvant Chemotherapy (NACT)

Agrawal

Mishra

et al. 2021

JAMMR

View full text Add to dashboard Cite

Introduction: Breast cancer commonly presents in locally advanced stage (LABC) in developing countries, for which NACT followed by surgery and radiotherapy is the standard of care. There is a need for a simple tool to risk categorise patients in the clinic, so that treatment intensification can be offered to women with high risk of recurrence. Materials and Methods: Data of prospectively maintained database of LABC (between January 2007 - December 2012), who received NACT followed by surgery, radiotherapy and endocrine therapy was retrospectively analysed for clinico-pathological factors associated with disease recurrences. A recurrence risk scoring model was developed on the basis of regression coefficient of identified independent risk factors. Results: In the data set of 206 patients, the median follow-up was 48 months (range: 6-156 months) and mean and median disease-free survival (DFS) were 87.41 and 85 months. The 1, 5, 10 years DFS was 95%, 54% and 41%. The independent risk factors (on modified p value <0.40) for recurrence were Tumour stage, Nodes stage, grade, age groups, pathologic complete response, intrinsic subtype, and type of surgery. Risk score prepared by regression coefficient (β), was in the range of 1-8 with median score of 5. ROC curve showed that area under ROC Curve of the score was 71.8% (95% CI: 64.8%-78.8%, p<0.001). To detect recurrences, a risk score ≥3 had at least 93.1% sensitivity and 31.9% specificity whereas score ≥4 had at least 73.5% sensitivity and 59.6% specificity. Based on cluster analysis, score 1-4 was identified as low risk whereas 5-6 as moderate risk group and ≥7 identified as high-risk group and their mean/median disease free survival time were 107.86/ NR, 66.99/30 months and 58.34/20 months respectively. Conclusions: The significant difference in DFS among three risk groups, indicates goodness of the fit of our risk score model. The risk scoring model developed by us is simple, easy to use in clinic and can be used for selecting high risk patients who benefit from treatment intensification.

show abstract

Section: Discussionsupporting

confidence: 92%

A Simple Risk Scoring System for Predicting Recurrence in Women with Locally Advanced Breast Cancer (LABC) Treated with Neoadjuvant Chemotherapy (NACT)

Agrawal

Mishra

et al. 2021

JAMMR

View full text Add to dashboard Cite

show abstract

“…In this study, it was found that the type of TNBC cancer was the type that experienced the most recurrences compared to the others. in this study it was found that the type of TNBC cancer will express STC1 strongly, this is in accordance with research conducted by Brantley which states STC1 as a predictor of recurrence in TNBC subtype, as previously known that TNBC subtype is a cancer with worst prognosis amongst all types of breast cancer [10], [16], [17], [18]. Score > 6.7 while in Figure 2b and c with Allred Score ≤ 6.7.…”

Section: Discussionsupporting

confidence: 91%

Expression of Stanniocalcin-1 as a Predictor of Recurrence in Breast Cancer Patients

Prajoko

Hastari

Muniroh

et al. 2022

Open Access Maced J Med Sci

View full text Add to dashboard Cite

Introduction: About 40% of breast cancer patients will experience a recurrence and the life expectancy will decrease from 95% to 40%. Stanniocalcin-1 is a biomarker that is thought to have potential as a risk factor for recurrence. Objective: To determine the role of Stanniocalcin-1 (STC1) expression as a risk factor for recurrence in breast cancer patients. Methods: Cross sectional observational study on breast cancer patients, assessed the clinicopathological character and seen whether the patient's condition had a recurrence. Immunohistochemical staining with STC1 antibody was performed on the patient's paraffin block. Reading of immunohistochemical preparations using the Allred score method by looking at 5 fields of view. Data analysis regarding the relationship between STC1 and recurrence was carried out using the Chi-Square test or Fisher's Exact test, then Logistic regression analysis was performed to determine the significant relationship between risk factors for recurrence. Results: Expression of STC1 was significantly different in patients who had recurrence and who did not experience recurrence (p= 0.000). There was a significant relationship between STC1 expression with age, tumor size, lymph node status, type of cancer, estrogen receptor status and stage at diagnosis. (p<0.005). Conclusion: It can be concluded that STC1 has a strong relationship with recurrence, so it has the potential to be used as a predictor of recurrence in breast cancer.

show abstract

“…Recently, the incidence of postoperative recurrence for intracranial metastases was reported to be significantly higher in basal and HER2-positive breast cancer subtypes with similar correlations observed for the postsurgical recurrence of primary breast cancers. [58,59] These findings suggest that a potential negative impact of invasive surgical procedures is the acceleration of dissemination and growth for BM originating from breast cancer subtypes with well-defined vascular signatures.…”

Section: Surgerymentioning

confidence: 92%

Heterogeneity and vascular permeability of breast cancer brain metastases

2020

View full text Add to dashboard Cite

Improvements in the diagnosis and treatment of systemic breast cancer have led to a prolongation in patient survival. Unfortunately, these advances are also associated with an increased incidence of brain metastases (BM), with the result that many patients succumb due to BM treatment failure. Intracranial delivery of many chemotherapeutic agents and other therapeutics is hindered by the presence of an impermeable blood-brain barrier (BBB) designed to protect the brain from harmful substances. The formation of BM compromises the integrity of the BBB, resulting in a highly heterogeneous blood-tumor barrier (BTB) with varying degrees of vascular permeability. Here, we discuss how blood vessels play an important role in the formation of brain micrometastases as well as in the transformation from poorly permeable BM to highly permeable BM. We then review the role of BTB vascular permeability in the diagnostics and the choice of treatment regimens for breast cancer brain metastases (BCBM) and discuss whether the vasculature of primary breast cancers can serve as a biomarker for BM. Specifically, we examine the association between the vascular permeability of BCBM and their accumulation of large molecules such as antibodies, which remains largely unexplored.

show abstract

Influence of the subtype on local recurrence risk of breast cancer with or without radiation therapy

Cited by 11 publications

References 20 publications

A Simple Risk Scoring System for Predicting Recurrence in Women with Locally Advanced Breast Cancer (LABC) Treated with Neoadjuvant Chemotherapy (NACT)

A Simple Risk Scoring System for Predicting Recurrence in Women with Locally Advanced Breast Cancer (LABC) Treated with Neoadjuvant Chemotherapy (NACT)

Expression of Stanniocalcin-1 as a Predictor of Recurrence in Breast Cancer Patients

Heterogeneity and vascular permeability of breast cancer brain metastases

Contact Info

Product

Resources

About